Tepezza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of thyroid eye disease, advancements in monoclonal antibody development, expansion of specialty infusion centers, rising awareness of autoimmune ophthalmic disorders, improved clinical trial outcomes for biologics.

The growth in the forecast period can be attributed to increasing demand for targeted autoimmune therapies, expansion of biologic treatment pipelines, growing investments in rare disease drug development, rising focus on personalized ophthalmology treatments, increasing adoption of outpatient infusion services. Major trends in the forecast period include increasing adoption of igf-1r targeted therapies, rising use of monoclonal antibodies for autoimmune conditions, growing focus on disease-specific biologic treatments, expansion of infusion-based specialty drugs, enhanced patient monitoring during therapy.

The rising incidence of thyroid diseases is expected to drive the growth of the Tepezza market going forward. Thyroid diseases encompass conditions that affect the structure or function of the thyroid gland, a butterfly-shaped organ located in the neck. The increasing incidence of thyroid disorders is attributed to factors such as improved diagnostic techniques, including high-resolution ultrasound and fine-needle aspiration, which enable earlier detection of abnormalities. Tepezza (teprotumumab) treats thyroid eye disease by inhibiting the insulin-like growth factor-1 receptor (IGF-1R), reducing inflammation, swelling, and proptosis around the eyes. For instance, in September 2025, according to Cancer Research UK, approximately 6,600 new cases of thyroid cancer are projected annually by 2038-2040, with incidence rates expected to increase by 27%, from roughly 7.3 cases per 100,000 people per year in 2024-2026 to about 9.2 per 100,000. Therefore, the rising incidence of thyroid diseases is fueling the growth of the Tepezza market.

Key companies in the Tepezza (teprotumumab-trbw) market are securing regulatory approvals to expand its indications beyond thyroid eye disease (TED). Regulatory approvals involve formal authorization from health agencies, ensuring a drug’s safety, efficacy, and quality for specific medical uses. For example, in April 2023, Horizon Therapeutics plc, an Ireland-based biotechnology company, announced that the FDA updated the indication for TEPEZZA, allowing its use in TED patients regardless of disease activity or duration. This change enhances access for all eligible TED patients, as TEPEZZA is the first and only FDA-approved therapy specifically for this condition. The approval is supported by Phase 4 clinical trial data demonstrating TEPEZZA’s effectiveness in reducing eye bulging in patients with long-standing TED, improving timely access to therapy and patient outcomes.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition strengthens Amgen’s position in rare and inflammatory disease treatment by incorporating Horizon’s portfolio, which includes Tepezza for thyroid eye disease, Krystexxa for chronic gout, and Uplizna for autoimmune conditions. The move expands Amgen’s offerings in critical therapeutic areas and accelerates growth in the inflammation space. Horizon Therapeutics plc, a US-based pharmaceutical company, continues to offer Tepezza as a targeted treatment for thyroid eye disease (TED).

Major companies operating in the tepezza market are Amgen Inc.

North America was the largest region in the tepezza market in 2025. The regions covered in the tepezza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tepezza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the tepezza market by increasing costs of imported biologic manufacturing equipment, active pharmaceutical ingredients, sterile fill-finish materials, and cold-chain distribution systems. Specialty infusion centers and hospital pharmacies in North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces higher costs for contract manufacturing services. These tariffs are increasing treatment costs and affecting pricing strategies. At the same time, they are encouraging domestic biologics production, local fill-finish investments, and strengthened regional supply chains for monoclonal antibody therapies.

The tepezza market research report is one of a series of new reports that provides tepezza market statistics, including tepezza industry global market size, regional shares, competitors with a tepezza market share, detailed tepezza market segments, market trends and opportunities, and any further data you may need to thrive in the tepezza industry. This tepezza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tepezza is a prescription medication containing teprotumumab-trbw, a monoclonal antibody that targets and inhibits the insulin-like growth factor-1 receptor (IGF-1R). It is used to treat thyroid eye disease (TED), a rare autoimmune disorder affecting the muscles and tissues around the eyes, leading to inflammation, swelling, and vision problems.

The primary clinical indications for Tepezza include thyroid eye disease (TED), orbital inflammatory diseases, and other inflammatory ocular conditions. Thyroid eye disease is an autoimmune disorder characterized by inflammation of the tissues surrounding the eyes, often associated with thyroid dysfunction. Tepezza can be administered via intravenous or subcutaneous routes and is distributed through hospital and online pharmacies. End users include adult and geriatric patients.

The tepezza market consists of sales of pre-filled syringes, pen devices, and lyophilized powders for reconstitution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.